Obesity-related hypertension: Pathogenesis, cardiovascular risk, and treatment—A position paper of the The Obesity Society and the American Society of Hypertension


  • Disclosure: This joint position paper also published in Journal of Clinical Hypertension. (Landsberg L, Aronne L, Beilin L, Burke V, Igel L, Lloyd-Jones D, Sowers, J. Obesity Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment. Journal of Clinical Hypertension 2012;doi:10.111/jch.12049.

  • Conflict of interest: Dr. Landsberg discloses no relevant or financial conflicts of interest. Dr. Sowers discloses participation in 2 NIH grants and is an advisory board member for Merck. Dr. Beilin discloses no relevant or financial conflict of interest. Dr. Burke discloses no relevant or financial conflicts of interest. Dr. Igel discloses no relevant or financial conflicts of interest. Dr. Lloyd-Jones discloses no relevant or financial conflicts of interest. Dr. Aronne discloses participation in contracted research with Amylin Pharmaceuticals Inc, High Point Pharmaceuticals LLC, Medical University of South Carolina and Novo Nordisk. Dr. Aronne is a consultant or on the Advisory Boards for the following: Amylin Pharmaceuticals Inc, Ethicon Endo-Surgery Inc, GlaxoSmithKline Consumer Healthcare LP, Novo Nordisk, Orexigen Therapeutics Inc, VIVUS Inc, Takeda Pharmacueticals and Zafgen Inc. Dr. Aronne has ownership interest in Cardiometabolic Support Network LLC and Myos Corporation. No funding or editorial support was provided for this article.


In light of the worldwide epidemic of obesity, and in recognition of hypertension as a major factor in the cardiovascular morbidity and mortality associated with obesity, The Obesity Society and The American Society of Hypertension agreed to jointly sponsor a position paper on obesity-related hypertension to be published jointly in the journals of each society. The purpose is to inform the members of both societies, as well as practicing clinicians, with a timely review of the association between obesity and high blood pressure, the risk that this association entails, and the options for rational, evidenced-based treatment. The position paper is divided into six sections plus a summary as follows: pathophysiology, epidemiology and cardiovascular risk, the metabolic syndrome, lifestyle management in prevention and treatment, pharmacologic treatment of hypertension in the obese, and the medical and surgical treatment of obesity in obese hypertensive patients. Obesity (2012)